Eli Lilly and Company (LLY)

 

We are in a collaborative arrangement with Daiichi Sankyo Company, Limited (D-S) to develop, market, and promote prasugrel, an antiplatelet agent for the treatment of patients with acute coronary syndromes (ACS) who are being managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). Prasugrel was approved for marketing by the European Commission under the tradename Efient in February 2009. We have submitted a new drug application to the FDA and are currently awaiting its decision. Within this arrangement, we have agreed to co-promote under the same trademark in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. D-S has exclusive marketing rights in Japan. Pursuant to the terms of the agreement, we paid D-S an upfront license fee and agreed to pay future success milestones. Both parties share in the costs of the development and marketing in the co-promotion territories and share in the profits according to the terms specified in the agreement. D-S is responsible for supplying bulk product, but we will produce the finished product for our exclusive and co-promotion territories. Profits in the U.S. and other co-promotion territories will be shared according to the agreement. In our exclusive territories, we will pay D-S a royalty specific to those territories. Profit share payments made to D-S will be recorded as marketing, selling, and administrative expenses. All royalties paid to D-S will be recorded in cost of sales.

 

 

We are in a collaborative arrangement with Daiichi Sankyo
Company, Limited (D-S) to develop, market, and promote
prasugrel, an antiplatelet agent for the treatment of patients
with acute coronary syndromes (ACS) who are being managed with
an artery-opening procedure known as percutaneous coronary
intervention (PCI). Prasugrel was approved for marketing by the
European Commission under the tradename Efient in February 2009.
We have submitted a new drug application to the FDA and are
currently awaiting its decision. Within this arrangement, we
have agreed to co-promote under the same trademark in certain
territories (including the U.S. and five major European
markets), while we have exclusive marketing rights in certain
other territories. D-S has exclusive marketing rights in Japan.
Pursuant to the terms of the agreement, we paid D-S an upfront
license fee and agreed to pay future success milestones. Both
parties share in the costs of the development and marketing in
the co-promotion territories and share in the profits according
to the terms specified in the agreement. D-S is responsible for
supplying bulk product, but we will produce the finished product
for our exclusive and co-promotion territories. Profits in the
U.S. and other co-promotion territories will be shared
according to the agreement. In our exclusive territories, we
will pay D-S a royalty specific to those territories. Profit
share payments made to D-S will be recorded as marketing,
selling, and administrative expenses. All royalties paid to D-S
will be recorded in cost of sales.